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With the emergence of transcatheter solutions for the treatment of tricuspid regurgitation
(TR) increased attention has been directed to the once neglected tricuspid valve (TV)
complex. Recent studies have highlighted new aspects of valve anatomy and TR etiology.
The assessment of valve morphology along with quantification of regurgitation severity
and RV function pose several challenges to cardiac imagers guiding transcatheter valve
procedures. This review article aims to give an overview over the role of modern imaging
modalities during assessment and treatment of the TV.
Keywords: tricuspid regurgitation, valvular heart disease, tricuspid interventions, imaging of tricuspid valve,
annuloplasty, edge-to-edge repair, caval stent, valve replacement
INTRODUCTION
Since the recent emergence of percutaneous valve interventions as a possible alternative to surgery
or medical treatment, tricuspid valve (TV) disease has attracted growing attention. Although
tricuspid regurgitation (TR) of any severity is present in about 70% of the population (1), in
the past this entity has been neglected in daily clinical practice. Severe TR affects around 4% of
the population over 75 years of age, with higher prevalence in women, elderly patients, and in
those who already underwent open-heart surgery for left-sided heart valve disease. This number is
expected to rise in the future due to population aging (2–4).
Multiple observational studies have reported worse survival in patients with severe TR,
irrespective of left and right ventricular function, pulmonary artery pressure, age, gender and
co-morbidities (2, 5–10). In patients undergoing left-sided heart valve surgery or interventional
treatment, the presence of relevant TR has been identified as a predictor of poor outcomes (11, 12).
A recent propensity-matched cohort study showed that transcatheter TV interventions might be
able to improve prognosis compared to medical treatment alone (13).
Imaging the TV and grading TR is challenging as transfer of existing knowledge and
recommendations from the left side of the heart is not always possible. In contrast to the mitral
valve, the TV operates in a low pressure environment with slower jet velocity. In addition,
valve geometry, TR proximal flow convergence zone, and jet morphologies are more complex,
making the usual tools and geometrical assumptions less accurate (14). The high variability of
TR depending on small preload changes (e.g., during the respiratory cycle) (15), represents an
additional difficulty (2, 16).
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MORPHOLOGY AND ANATOMICAL
RELATIONS
Autoptic studies have enhanced the anatomical understanding
of the TV (17–19). Indeed, despite its name, the TV is truly
tricuspid in only 57% of the investigated subjects (20). In the
remaining 43%, it is quadricuspid with an additional leaflet,
generally located between the septal and the posterior ones.
The healthy tricuspid annulus has a three-dimensional saddle-
shaped elliptical geometry (15, 21–23). Its anterior and posterior
portions are muscular, whereas the septal part is more fibrous,
which explains predominant antero-posterior annular dilation
as well as the spherical and planar shape of the annulus in
patients with severe functional TR (11, 24). The tricuspid
annulus is contiguous to several important anatomical structures
(25). The postero-septal portion is close to the ostium of the
coronary sinus, delimiting the triangle of Koch, where both the
atrio-ventricular (AV) node and His-bundle are located. The
antero-septal aspect of the annulus is situated next to the right
ventricular outflow tract and the right coronary artery ostium.
In its further course, the right coronary artery circumscribes the
anterior and posterior portion of the annulus (11, 26) which
exposes it to a risk of compression, kinking or occlusion during
annuloplasty procedures, especially when located close to the
hinge point of the TV leaflets. Although no data exist, a distance
of <2mm has been suggested as a possible cut-off and is found
in 13–28% of the patients (27, 28).
ETIOLOGY AND MECHANISMS OF TR
TR etiology can be divided in primary (or organic) TR due
to leaflet abnormalities, and secondary (or functional) TR due
to annular and right atrial, or right ventricular dilation (25).
Diseases leading to leaflet deformation can be either acquired,
such as rheumatic or carcinoid heart disease, endocarditis,
trauma, or congenital, like Ebstein’s anomaly and endocardial
cushion defect (29). Functional TR accounts for up to 94% of
moderate to severe TR cases, with 49% occurring in the context
of left-sided valvular disease, 23% concomitantly to relevant
pulmonary hypertension (systolic pressure ≥50 mmHg), 13% in
association with left ventricular dysfunction and 8% in isolation
without any of the previously mentioned causes (2). Isolated TR
was an independent predictor of all-cause mortality even after
adjustment for various confounders (2). Increasing TR severity
correlates with a higher cardiovascular mortality rate (2, 5, 9, 10).
TR leads to volume overload and further RV and RA dilation,
resulting in annulus dilation, papillary muscle displacement and
leaflet tethering, also influenced by elevated pulmonary artery
pressure, further aggravating valve dysfunction (30, 31). TR
not only has a mechanical effect on the right heart structures,
Abbreviations: 2D, two-dimensional; 3D, three-dimensional; AROA, anatomic
regurgitant orifice area; CMR, cardiac magnetic resonance imaging; MSCT,
multislice computed tomography; EROA, effective regurgitant orifice area; PISA,
proximal isovelocity surface area; RV, right ventricle; TV, tricuspid valve; TEE,
transesophageal echocardiography; TR, tricuspid regurgitation; TTE, transthoracic
echocardiography; VC, vena contracta; VCA, vena contracta area.
but also increases stiffness of the RA, possibly due to chronic
inflammatory processes and formation of interstitial fibrosis
(32). Patients with associated right ventricular dysfunction,
independently from RV dilation, have a particularly unfavorable
clinical prognosis (33).
Chronic atrial fibrillation can be either the cause or the result
of TR. Studies report a high overall prevalence of chronic atrial
fibrillation in patients with moderate or severe TR (up to 68%)
with a yearly incidence of 28% in the setting of associated
left-sided valvular heart disease and 13% in isolated TR (2).
Conversion to sinus rhythm may effectively reduce TR (34).
TR in the presence of cardiac implantable electronic devices-
leads (CIED) is a topic of growing concern due to the rising
number of implantations. New-onset significant TR after CIED
placement has been observed in up to 38% of the patients,
either resulting from direct valve injury or adverse interaction
with the leaflets, most commonly affecting the septal leaflet
(35), or the subvalvular apparatus (36, 37). Due to frequently
associated left ventricular dysfunction and comorbidities acting
as confounders, the causality of the higher mortality observed
in patients with CIED-related TR is difficult to establish (38).
The localization of the lead appears to influences the severity of
TR. While a lead implanted in the interventricular septum has a
higher risk of leaflet impingement, amore commissural or central
position seems less problematic (37, 39). Interestingly, leadless
pacemaker may also contribute to TV dysfunction because
of either ventricular dyssynchrony induced by RV pacing or
unintended interaction with the subvalvular apparatus (40, 41).
GRADING TRICUSPID REGURGITATION
SEVERITY
Imaging the TV is associated with particular challenges
summarized in Table 1. TR severity should be assessed in an
integrative way using various echocardiographic parameters,
as well as adjunctive imaging modalities such as multislice
computed tomography (MSCT) and cardiac magnetic resonance
imaging (CMR), when echocardiographic quality is poor or
severity parameters are discordant (14).
Due to the anterior position of the RV close to the chest,
transthoracic echocardiography usually provides satisfactory
imaging quality for severity grading (42). Advanced anatomical
TABLE 1 | Challenges of imaging the tricuspid valve.
Challenges of TV Imaging
• Variable and fragile anatomy
• High (pre- and after-) load dependancy
• Low pressure environment / slower jet velocity
• Presence of CIED-leads
• Artifacts from left-sided bioprosthetic valves
• Limited evidence and experience
• Not or insufficiently validated cut-off values
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assessment typically requires a dedicated 3D transesophageal
echocardiography (TEE) study owing to higher spatial resolution.
An integrative approach considering identical parameters
using different imaging modalities is likely to improve the
diagnostic accuracy.
Quantitative and semi-quantitative parameters considered
useful for grading TR include the following:
Color Jet Area
Echocardiographic measurement of the color jet area using
the 4-chamber, RV inflow or subcostal views is indicative of
severe TR if the jet area exceeds 10 cm². It is physiologically
influenced by direction, momentum and velocity of the jet and
the systolic pressure difference between RV and RA (43), and
technically by the color scale and wall filter settings, as well as
the transducer frequency (14). Importantly, in very severe TR an
early equalization of the pressure between the RV and the RA
can occur, leading to a very low velocity with almost no visible
jet (30).
Flow Reversal in the Hepatic Veins
Flow reversal into the hepatic veins is a specific parameter (if
present:>85% probability of severe TR) (44), but with rather low
sensitivity, as the venous flow patterns depend on various factors
including RA dimensions and compliance, RV function, as well
as atrial fibrillation or pacemaker stimulation (11, 30). A reflux of
contrast medium into the inferior vena cava with enhancement of
the mid to distal hepatic veins onMSCT is also considered highly
specific for significant TR (45).
Tricuspid Inflow Velocity
Tricuspid inflow velocity can be used as a complementary
method to grade TR. A peak tricuspid E-wave velocity>1.0m/sec
has been associated with right ventricular pathology (46) and
severe TR (47). The tricuspid inflow velocity represents a simply
obtained measurement, but has to be carefully interpreted in the
context of age and heart rate.
Vena Contracta (VC)
VC is defined as the narrowest width of the color regurgitant
jet and is usually measured directly below the proximal flow
convergence zone. Severe TR is defined as a VC width ≥
7mm in the RV inflow view according to current guidelines,
a value that has been associated with worse cardiovascular
outcomes (1, 48–50). Due to triangular and elongated shape
of the regurgitant orifice in TR, a single 2D measurement of
the VC only insufficiently reflects the anatomical reality. Song
et al. (51) have proposed the use of different VC width cutoff
values for severe TR depending on the plane of the view: 8.4mm
in the septo-lateral and 12.6mm in the antero-posterior view,
respectively. Dahou et al. (52) have also suggested measurement
in two orthogonal planes with an average VC cutoff of ≥ 9mm.
The VC widths measured in the septo-lateral projection were 3.9
± 3.7mm smaller than the one measured in the antero-posterior
direction and discrepancies were found to worsen with increasing
TR severity. To overcome these limitations, measurement of the
3DDoppler VC area using multiplanar reconstruction (Figure 1)
may be considered (52, 53) Cut-offs for severe TR ranging from
0.37 to 0.75 cm² have been proposed (51–53).
Regurgitant Volume
The regurgitant volume can be derived from the stroke volumes
(SV) assessed by quantitative Doppler and is calculated as the
antegrade tricuspid diastolic SV minus the left ventricular or
right ventricular outflow forward SV. In the presence of more
than mild aortic regurgitation, the right ventricular forward SV
should be preferred, and vice versa. In both cases, the SV is
obtained from the diameter (D) and the velocity time integral
(VTI) of either the right or left ventricular outflow tract as
(D/2)2 × π × VTI.
FIGURE 1 | Example of 3D Doppler VC area using multiplanar reconstruction. (A,B) Reformation planes are aligned at the height of the 2D vena contracta during
systole in two different planes. (C) A1 measures 1.65 cm2 in this case.
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TABLE 2 | Example of a dedicated computed tomography protocol for the
tricuspid valve.
Examination protocol for ECG-gated computed tomography of the TV
• 2 × 128 row stellar detector (e.g., Siemens SOMATOM Definition Flash)
• Inspiratory breath-hold, single-volume acquisition
• Retrospective ecg-triggered acquisition over the whole cardiac cycle (0–100%
R-R interval)
• Isotrophic resolution 0.33 × 0.33mm, crossplane 0.30mm;
gantry rotation time 280ms; temporal resolution 750 ms
• Tube voltage 100–120 kV, tube current 240 reference mAs (care dose)
• Intravenous injection of non-ionic contrast agent (iopromide)
• 50ml contrast medium at a rate of 4 ml/s, followed by
• 30ml contrast medium at a rate of 3 ml/s, followed by
• 20ml of saline at a rate of 4 ml/s
• total contrast volume = 80ml
• Real-time bolus tracking with automated peak enhancement detection with
region of interest ascending aorta, based on a threshold of 120 Hounsfield units
• Reconstruction of the 3D data set from the contrast-enhanced scan at 5%
increments throughout the cardiac cycle with a slice thickness of 0.75 mm
The tricuspid diastolic SV by quantitative Doppler is
calculated through multiplication of the tricuspid annular area
(preferably measured on 3D multiplanar reconstruction) by
the pulsed-wave Doppler VTI through the annulus (54, 55).
The tricuspid diastolic SV may be overestimated in case of
heterogeneous and complex annular flow patterns (54). Despite
interobserver variability, the volume derived from quantitative
Doppler assessment correlates well with other echocardiographic
parameters (56) and has a prognostic value in patients with TR
and reduced left ventricular function (8).
Using 4D MSCT the regurgitant volume and fraction are
derived from the difference between RV and LV stroke volume
obtained by ventricular volumetry. Higher saptial resolution may
represent an advantage, but cutoffs to grade TR severity have not
been established yet (14, 57). Table 2 shows an example of a CT
protocol dedicated to the tricuspid valve. The use of a mixture
of saline/contrast is considered helpful to increase the contrast
travel time and minimize streak artifacts (58).
Using CMR, the TR jet can be visualized based on its signal
void with cine imaging. Quantitative TR severity is calculated
indirectly. The forward flow volume is obtained from through-
plane phase-contrast velocity mapping in the pulmonary artery.
After substraction of the forward volume measured in the
pulmonary artery from the total RV stroke volume assessed by RV
volumetry (ciné steady-state free precession imaging), absolute
TR regurgitant volume and fraction can be calculated (59). More
recently, 4D-flow CMR has been used for 3D quantification
of TR and can correct for through-plane motion as well as
eccentricity, with high intra- and interobserver reproducibility
and high consistency with 2D phase contrast velocity mapping
and echocardiography (60, 61).
Effective Regurgitant Orifice Area (EROA)
Traditionally, an EROA by proximal isovelocity surface area
(PISA) ≥ 40 mm² indicates severe TR. Calculation of the EROA
according to the PISA method is based on the assumption of
a circular orifice and thus disregards the complexity of the TV,
resulting in underestimation of TR severity in one third of
patients. Assessment of PISA by 3D-color echocardiography may
overcome this limitation by providing a more realistic picture of
the actual geometry of the flow convergence zone. However, it
may underestimate the actual surface area of the PISA due to
angle dependency of the color-Doppler. In addition, PISA only
accounts for a single time point and therefore does not integrate
the potentially dynamic nature of the flow (42). Alternatively, the
EROA can be derived from the quantitative Doppler method,
which has been shown to better approximate the planimetric
3D Doppler VC area (14). A possible implementation concept
would be the assignment of different cut off values to PISA- and
Doppler-derived EROA (52).
3D Integrated PISA
Instead of using a single PISA to calculate the regurgitant volume,
the concept of integrated PISA accounts for temporal changes
of the regurgitant flow during systole. With this method, a 3D
PISA is reconstructed for each frame of the acquired loop. The
flow of each PISA corresponds to its area multiplied by the
chosenNyquist velocity. As explained in Figure 2, the regurgitant
volume is obtained by summation according to the duration of
each frame. In patients with mitral regurgitation, it best estimates
the regurgitant volume compared to CMR with high sensitivity
(100%) and specificity (96%) for the detection of severe MR (62).
Anatomic Regurgitant Orifice Area (AROA)
As recently described for the mitral valve (63), measurements
of the anatomic regurgitant orifice by CT are feasible and may
be considered as an additional grading tool in patients with
discrepant echocardiographic measurements.
In our experience, the values obtained using multiplanar
reconstruction (Figure 3) are generally larger than the
corresponding 3D Doppler VC area that rather reflects the
effective regurgitant orifice after contraction of the flow stream.
However, both parameters significantly correlate (Figure 3C), so
that AROA may help to identify patients with severe TR.
Need for a New Grading Scheme
Since many patients present at a very advanced stage of
the disease, current thresholds for severity grading may not
sufficiently reflect the variability of the clinical presentation. For
this reason, a new grading scheme including the two additional
grades “massive” and “torrential” with corresponding cut-offs
has recently been proposed (64, 65) and used in clinical studies
(66, 67). Preliminary data show an incremental prognostic value
of the new classification beyond “severe” (68, 69). In addition,
the proposed scheme may allow better appraisal of the results
following interventional procedures.
ASSESSMENT OF THE RIGHT
VENTRICULAR FUNCTION
RV function has an important prognostic value in patients with
TR (33) and, in the absence of elevated afterload, represents a
marker of severity and duration of TRmediated volume overload.
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FIGURE 2 | Integrated PISA with three-dimensional reconstruction of 6 PISAi during systole using a Nyquist limit of 22.8 cm/s. This reconstruction highlights the
complex shape of the TR PISA and its change in size and shape across systole. The following formula is used to calculate the 3D-PISAi flow: 3D-PISAi flow =
3D-PISA*iNyquist-velocity. The RegVoli of each PISAi is derived using the duration of each frame (1/Volume rate, in this case 0.05 s): RegVoli = 3D-PISAi flow*0.05.
The total RegVol is the summation of the RegVoli of each frame.
FIGURE 3 | Multiplanar reconstruction of the anatomic regurgitant orifice area (AROA) on MSCT images. (A) The reformation planes are adjusted at the leaflet tips
during systole (20–40%). (B) The regurgitant orifice is delineated on the short axis. The AROA in this case is 0.7 cm2. (C) Correlation between TEE color-Doppler 3D
vena contracta area (VCA) and MSCT AROA obtained with multiplanar reconstruction.
CMR is considered the gold standard for evaluating the
RV dimensions and function due to high spatial resolution
and accurate volumetric 3D assessment (without the use of
geometrical assumptions) (70).
RV ejection fraction is highly dependent on pre- and afterload,
and for this reason, probably suboptimal for the evaluation of
RV function in the presence of pulmonary hypertension and/or
severe TR (57, 71). Tricuspid annular plane systolic excursion
(TAPSE) and tissue-Doppler derived right ventricular excursion
velocity (DTI) measured by transthoracic echocardiography
are reliable compared to CMR (72). On the other hand,
load dependency and variability according to measurement
angle represent potential limitations (73). Moreover, the RV
contractile pattern shifts after cardiac surgery further decreasing
its reliability.
To overcome these specific drawbacks, new methods have
been proposed. Using 2D spackle tracking, the longitudinal strain
can be derived in all RV segments. This measure correlates
well with the RV ejection fraction by CMR (74) and has been
validated in patients with various cardiovascular conditions
(75, 76) Recent studies have confirmed the high sensitivity
of RV strain for the identification of RV dysfunction in the
context of severe TR (77, 78). The right ventricular change in
pressure over time (dP/dT), as assessed by echocardiography
has been proposed as a novel parameter reflecting RV
contractility and correlates well with CMR RV ejection
fraction (77–79).
In contrast, 3D echocardiographic volumetric quantitation
of the RV in different planes is limited by the need
for clear delineation of the endocardial borders. Published
data, which may overestimate the feasibility of this complex
method, show a good correlation for systolic function, but
a systematic underestimation of volumes in comparison to
CMR (11, 73, 80).
Although less investigated, RV function, dimensions, and
volumes may also be reliably obtained from a dedicated 4D
electrocardiogram-gated MSCT (81) and normative values have
been published (82).
PATIENT SELECTION AND PROCEDURAL
PLANNING
Multimodality imaging is essential for patient selection as well
as procedural planning. Moreover, it may help to anticipate and
prevent complications and thereby improve outcomes. Table 3
provides an overview of the specific roles of the different imaging
modalities for pre-procedural planning and guiding.
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TABLE 3 | Overview of the role of the different imaging modalities for
preprocedural planning and intraprocedural guiding.
Preprocedural Intraprocedural
Echocardiography/
ICE
• TR mechanism and severity
• Assessment of RV function
• Estimation of RA and
pulmonary pressures
• Visualization of catheters
and leads
• Identification of target
points
• Assessment of immediate
result
• Fusion imaging
Multislice
computed
tomography
(MSCT)
• Measurement of annulus
and RV dimensions
• Asssessment of subvalvular
apparatus
• Localization of surrounding
structures (CS, IVC, SVC,
RCA) and implantation site
• Implant simulation, 3D
printing and
access reconstruction
Calculation of optimal
fluoroscopic viewing angles
Fluoroscopy Angiography of RCA • Navigation of access and
in right atrium
• Wiring and angiographic
depiction of RCA
• Valve deployment
Cardiac magnetic
resonance
• TR severity
• Assessment of RV function
–
Patient Selection
After thorough assessment of the underlying mechanism of TR,
RV function and the exclusion of severe pulmonary hypertension,
patients with persisting symptoms despite guideline-directed
medical therapy should be evaluated for an intervention by
the Heart Team. In patients with concomitant valvulopathy
or coronary artery disease requiring surgical revascularization,
open-heart surgery remains the first-line treatment. Patients at
low surgical risk with isolated severe TR may also be referred
for surgical valve repair or replacement, although evidence of an
impact on survival is lacking (83, 84) In patients at increased
surgical risk, transcatheter techniques may represent a valuable
alternative with potential impact on outcomes in terms of heart
failure hospitalization and mortality (13).
The surgical experience for valve repair has shown that a
tenting area ≥ 1.8 cm², a tenting height ≥ 0.8 cm and a tenting
volume≥ 2 cm3 are predictors of procedural failure for tricuspid
repair (85–87). In a similar way, a coaptation depth <10mm, a
central or antero-septal jet location, as well as a coaptation gap
of less than about 7mm have been identified as independent
predictors of procedural success for transcatheter interventions
(88, 89). In contrast, procedural failure (reduction of TR of
less than one grade) and elevated pulmonary pressures were
identified as independent predictors of mortality (88). Although
no study comparing different devices exist so far, specific system
characteristics may better address a given pathology.
The selection of the appropriate transcatheter treatment
solution should be based on the severity of annular dilation
and jet location. Patients with predominant annular dilation and
reasonable leaflet tethering are appropriate candidates for either
an annuloplasty device [e.g., Cardioband (67) or TriCinch (90)]
or leaflet approximation with either the MitraClip (66, 91, 92)
or the Edwards PASCAL system (93). A dedicated system, the
Abbott TriClip, is expected to be available soon. For treatment
of a central jet, direct annuloplasty may be preferred, while
patients with commissural TR are good candidates for leaflet
approximation. On the other end of the spectrum, patients
presenting late in the course of the disease with advanced
RV remodeling, severe leaflet tethering or large coaptation gap
should be evaluated for (bi-)caval valve implantation (94–96)
or transcatheter TV replacement (79). However, in patients
with advanced RV dysfunction, complete elimination of TR
through replacement of the valve may precipitate RV failure
and eventually lead to cardiogenic shock due to acute afterload
mismatch, particularly in the context of preexisting elevated
pulmonary vascular resistance and pulmonary hypertension (97).
As pulmonary artery resistance may not be reliably reflected
by the RV/RA-gradient or the mean invasive pulmonary artery
pressure in the presence of TR, it should be calculated based on
the values obtained during right heart catheterization. In cases of
CIED—lead induced TR, decision should be made individually
according to the above mentioned anatomic findings. Data from
the TriValve registry showed comparable procedural success and
clinical endpoints compared to patients without CIED lead (98).
Procedural Planning
A comprehensive echocardiographic assessment of the
underlying TR mechanism, localization of the regurgitation
jet(s) and if applicable, precise CIED-lead location and
assessment of its relation to the leaflets (mobile vs. adherent)
is crucial for procedural planning of any TV intervention.
Especially the TEE short axis view, obtained from transgastric,
or the surgical view, acquired by 3D imaging, delivers valuable
anatomical information. When aiming for TV repair using leaflet
approximation, the exact jet location as well the anticipated
implantation strategy (triple orifice vs. bicuspidization), and the
number of devices has to be determined. Coronary angiogram
should also be part of pre-procedural work-up to confirm
patency of the RCA.
Measurement of the TV annulus dimensions is another
important step during planning of annuloplasty or valve
replacement procedures. In contrast to the left side of the
heart, annular dimensions correlate closely with TR severity
due to the absence of a fibrous skeleton around the valve, and
predominantly functional etiology of TR. A cutoff of ≥ 14–15
cm² for the annular area is indicative of severe TR (14, 99). The
complex 3D elliptical shape of the TV annulus is best appraised
by TEE or CT using 3D semi-automated imaging techniques that
helps to minimize the impact of artifacts due to leads or left heart
bioprostheses (11, 99).
According to a recent study, measurement of the tricuspid
annulus by CMR is also feasible and reproducible (100).
PROCEDURAL GUIDING
Transcatheter tricuspid procedures are guided by 2D and real-
time 3D TEE in combination with fluoroscopy, which enables
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precise positioning of catheters and implants. Near-field views of
the TV are obtained using deep transesophageal and transgastric
positions of the TEE probe (101). A good acoustic transgastric
short axis window is essential to ensure procedural feasibility.
The different transcatheter techniques available have variable
imaging requirements as detailed in Table 4. The combined
skills of the interventional cardiologist and the imaging specialist
are essential and equipollent for the success of the procedure.
A consistent anatomical nomenclature has been proposed to
facilitate intraprocedural communication (102).
Leaflet Approximation
Transcatheter leaflet approximation is mainly guided by 2D
and 3D TEE (Figure 4A). For the orientation of the implant,
TABLE 4 | Role of imaging modalities for planning and guiding currently available
transcatheter procedures.
2D echo 3D echo MSCT Fluoroscopy
Leaflet approximation +++ ++ – + (+)
Annuloplasty +++ + +++ ++
Valve replacement +++ +++ +++ +
Caval valve
implantation
+ – +++ +++
a transgastric short axis view (30–50◦) of the TV is typically
obtained and allows for distinction of the commissures and
orientation of the device (Figure 4B). Grasping is performed
using an x-plane mid or distal esophageal view (50–75◦)
cutting either the antero-septal or postero-septal commissure
(Figures 4D,E), while the implant orientation is monitored
using fluoroscopy (Figure 4C). Bicuspidization or triple orifice
technique have been proposed as possible strategies.
Transcatheter Annuloplasty
Systematic MSCT analysis plays a crucial role for the planning
and guiding of direct annuloplasty. This includes the calculation
of optimal fluoroscopic viewing angles (Figures 5A,B), as well
as the systematic measurement of the distance between the
TV hinge point and the RCA (Figure 5C). Indeed, the RCA
is at risk for injury during the procedure, especially if located
in close proximity to the site of implantation. An “en face”
view of the TV is typically obtained on an LAO fluoroscopic
projection and allows for antero-posterior orientation alongside
the RCA (Figures 5B,D) and corresponds to the TEE transgastric
short axis view (103, 104). In this view, the ostium and
proximal part of the RCA surrounds the anterior valve leaflet
while the periphery is close to the posterior leaflet. As a
further orientation landmark, but also to facilitate a tentative
intervention, a coronary guidewire is placed into the RCA during
FIGURE 4 | Edge-to-edge repair case. (A) Assessment of the baseline valve anatomy using transesophageal 3D echocardiography (A=anterior leaflet; S=septal;
p=posterior). (B) Orientation of the clip perpendicular to the antero-septal commissure using the transgastric view. (C) Insertion of the delivery system into the right
atrium under fluoroscopic guidance (projection: RAO 20) after implantation of a MitraClip in the mitral valve (arrow). (D,E) Positioning of the clip in the postero-septal
commissure using x-plane mid-esophageal view (closer to the aorta is a first clip in the antero-septal commissure, *pacemaker lead). (F) Final result after implantation
of 2 clips.
Frontiers in Cardiovascular Medicine | www.frontiersin.org 7 May 2020 | Volume 7 | Article 60
Winkel et al. Imaging for TTVI
FIGURE 5 | Annuloplasty case. (A–C) Preprocedural MSCT planning of the Cardioband implantation (projection A: RAO 10—CRAN 10, B: LAO 76—CAU 15; green
line: reconstruction of the RCA). (A,B) Anticipated localization of the screws in relationship with the RCA. (C) Measurements of the distance between annulus and
RCA. (D) Angiography of the RCA after Cardioband cinching (projection: LAO 52—CAU 10) with “en face” view of the TV. The ostium and proximal part of the RCA are
in close proximity to anterior leaflet while the periphery is close to the posterior leaflet. (E) MultiView echocardiography for intra-procedural guiding of screw
implantation allowing catheter localization in three planes.
annuloplasty and valve replacement procedures. Visualization
of the vessel helps to estimate the distance between the first
screws and the aorta that is confirmed by TEE. A two-chamber
view with the annulus and RCA in plane is generally obtained
with a RAO caudal fluoroscopic projection (Figure 5A) and
translates into a 110–130◦ low-esophageal RV inflow view in
TEE (103). The relationship of each screw along the course
of the RCA also inform about the position of the catheter in
relation to the annulus (more atrial or ventricular). The use of
biplane fluoroscopy and 3D echocardiography with multiplanar
reconstruction (Figure 5E) enable simultaneous interrogation of
several imaging planes.
Transcatheter Tricuspid Valve Replacement
Procedural planning of transcatheter tricuspid valve replacement
requires detailed anatomic assessment of the tricuspid annulus
including measurements of area and perimeter for appropriate
valve sizing. Simulationmay be used to anticipate access and final
valve positioning. Centered position of the valve and deployment
are controlled by transesophageal echocardiography (79), and
optionally intracardiac echocardiography (105).
Caval Valve Implantation
For heterotopic caval valve placement, MSCT plays a central
role to assess the dimensions of the right atrium, identify
the ostium of the superior and inferior venae cavae, their
angulation and dimensions, as well as the distance to the
liver veins (Figures 6A,B). The procedure is then mainly
guided by fluoroscopy (Figure 6C), while transthoracic
echocardiography and possibly MSCT are used for clinical
follow-up (106).
Adjunctive Imaging and Visualization Techniques
Intracardiac echocardiography (ICE) is increasingly used to
guide transcatheter TV repair, currently as an adjunct to
TEE (107–109). Placed in a low right atrial position it
enables high resolution imaging of the TV and avoids artifacts
from the left side of the heart. Current systems are limited
by insufficient far-field imaging quality and the lack of
3D capabilities.
Fusion-imaging integrating echocardiography and/or
MSCT, and fluoroscopy require further validation for tricuspid
interventions. However, it has the potential to simplify
the procedural steps through sophisticated visualization of
anatomical structures and catheters/devices in relationship to
each other (101, 106, 110).
MSCT provides the necessary information for 3D printing
of anatomical models than can be used to simulate and train
complex TV procedures.
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FIGURE 6 | Heterotropic transcatheter caval valve implantation. (A) 3D MSCT reconstruction of the vena cava inferior, the liver veins and the right heart cavities. (B)
Schematic depiction of the NVT Tricento bicaval stenting device. (C) Fluoroscopic image of the implanted stent (projection: RAO 45). (D,E) Transthoracic
echocardiographic imaging of the implanted device in his long and short axis from subxyphoidal at 30-day follow-up. (F) Depiction of the prosthesis and its relation to
the right atrium and the hepatic vein in computed tomography. (Asterisk: valve element; arrow: leadless pacemaker; plus: hepatic vein).
ASSESSMENT OF RESULT
Assessment of interventional TR treatment efficacy using
echocardiography can be challenging, especially after leaflet
approximation procedures and/or when multiple TR jets are
created. In addition, the implanted devices may produce
acoustic shadows impairing correct evaluation of proximal
flow convergence and vena contracta. Until now, only in
vitro studies compared the echocardiographic evaluation of
multiple regurgitant orifices with an independent method (111).
From a theoretical point of view, only the PISA method
(2D or 3D), the volumetric methods and the 3D VCA
are appropriate for the quantitative evaluation of multiple
regurgitant orifice by summation. Two-dimensional VC widths
and jet areas cannot be summed. Changes of the hepatic
vein flow patterns are also helpful. However, none of these
parameters were tested against an independent method in
this setting.
CONCLUSION
The tricuspid valve complex challenges imaging specialists
and interventional cardiologists in many respects. Patients
with TR constitute a heterogeneous and polymorbid
population who frequently present late during the course
of the disease. Imaging plays a crucial role for the
understanding of the natural progression and underlying
mechanisms of the disease, as well as for the guiding
of transcatheter interventions. Further refinements of
current imaging methods will help to better select the
appropriate device for the right patient and simplify
transcatheter procedures.
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